An osteoporosis drug to be repurposed as COVID-19 treatment.
Italy says yes to trial osteoporosis drug for covid-19 in italy, a drug regulatory board approved the human clinical trials of an osteoporosis medication the drug will enable investigators to repurpose it as a covid-19 treatment preclinical studies suggest that the drug may decrease symptoms and reduce the infectiveness of patients if it works, it may become an inexpensive
Medication to combat this pandemic according to reuters, the link between the raloxifene and covid-19 was identified in a hormone commonly found in women this hormone, estrogen, would play a major role in the female reproductive system during puberty early studies found that estrogen provided some level of protection against the coronavirus in pre-menopausal women during
Menopause, women are prone to osteoporosis due to lower levels of estrogen when addressed, estrogen’s theorized protective effect may be restored therefore, some scientists believed that raloxifene may provide the same effect in pre-menopausal women but to prove that it actually works, investigators must conduct clinical trials to see the dynamics in women in a post by
Webmd, raloxifene is a generic drug used to treat bone loss in women after menopause what makes it like estrogen is its interaction with some parts of the body, which detects the drug like the hormone while other body parts treat the drug as an estrogen blocker thus, it is not recommended in women before menopause the drug is clinically approved to treat certain diseases,
Including invasive breast cancer, in women after menopause the upcoming raloxifene clinical trial will involve 450 patients at the lazzaro spallanzani national institute for infectious diseases in rome participants will randomly receive the drug or placebo for seven days the enrollment will last for 12 weeks, and 174 additional participants may be included in the final
Stage the trial is led by excalate4cov, a platform supported by the european commission and is powered by supercomputing centers in italy, germany, and spain raloxifene works by blocking the replication cycle of the coronavirus, slowing down the disease progression its potential against covid-19 was verified in over 400,000 molecules screened by supercomputers
Transcribed from video
Italy Says Yes to Trial Osteoporosis Drug for COVID-19 By ENewsTrends
